Amanda Jones

Amanda joins from Axsome Therapeutics, where she led the clinical development of the first and only oral NMDA receptor antagonist approved for treating major depressive disorder in adults (Auvelity®). Prior to joining Axsome, she had varying roles of increasing responsibility in clinical research & development at Salix Pharmaceuticals and United Therapeutics. Amanda earned her Doctor of Pharmacy degree and completed a post-doctoral fellowship in clinical research and drug development at UNC-Chapel Hill Eshelman School of Pharmacy. She earned her B.S. in Biochemistry from Florida State University.